José Manuel Pérez-García, Javier Cortés, Manuel Ruiz-Borrego, Marco Colleoni, Agostina Stradella, Begoña Bermejo, Florence Dalenc, Santiago Escrivá-de-Romaní, Lourdes Calvo Martínez, Nuria Ribelles, Frederik Marmé, Alfonso Cortés, Cinta Albacar, Geraldine Gebhart, Aleix Prat, Khaldoun Kerrou, Peter Schmid, Sofia Braga, Serena Di Cosimo, Maria Gion, Gabriele Antonarelli, Crina Popa, Emilia Szostak, Daniel Alcalá-López, Petra Gener, Jose Rodríguez-Morató, Leonardo Mina, Miguel Sampayo-Cordero, Antonio Llombart-Cussac
BACKGROUND: PHERGain was designed to assess the feasibility, safety, and efficacy of a chemotherapy-free treatment based on a dual human epidermal growth factor receptor 2 (HER2) blockade with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer (EBC). It used an 18 fluorine-fluorodeoxyglucose-PET-based, pathological complete response (pCR)-adapted strategy. METHODS: PHERGain was a randomised, open-label, phase 2 trial that took place in 45 hospitals in seven European countries...
April 3, 2024: Lancet